Molecular marker testing and reporting completeness for adult-type diffuse gliomas in the United States.

Corey Neff Gino CioffiKristin WaiteCarol KruchkoJill S Barnholtz-SloanQuinn T OstromJ Bryan Iorgulescu

Published in: Neuro-oncology practice (2022)

Initial BMM testing/reporting completeness for individuals with adult-type diffuse gliomas in the United States was promising, although patterns varied by hospital attributes and extent of resection.

Keyphrases

high grade
adverse drug
low grade
healthcare
childhood cancer